Three-month interim report (Q1) 2025 (unaudited)

Last updated: 2025.05.09

ITULATEK® approved for treatment of children and adolescents in Canada

Last updated: 2025.05.08

ALK enters into neffy® co-promotion agreement in the USA

Last updated: 2025.05.02

Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025

Last updated: 2025.04.29

ITULAZAX® tree pollen tablet approved for treatment of children in Europe

Last updated: 2025.04.23

Market Access Manager

EasyCruit ID
3477339
Department ID
189887
Location
Expire Date
Last updated: 2025.04.25

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

Last updated: 2025.04.03

Annual report 2024: ALK delivers 15% sales growth with profits up 65%

Last updated: 2025.03.24

Annual General Meeting in ALK-Abelló A/S on 13 March 2025

Last updated: 2025.03.24

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

Last updated: 2025.03.24